Third Rock led last year's $35m B round that also saw biotech company Genzyme's corporate venturing division join the investment consortium as a new investor and it remains on the company's share register, although not publicly mentioned in its latest $30m C round.
Bluebird Bio, a US-based biotechnology company formerly known as Genetix Pharmaceuticals, has raised $30m in its series C round without having peer Genzyme as a reinvestor.
Venture capital firm Arch Venture Partners led the round, and was joined by peers Third Rock Ventures, Forbion Capital Partners (renamed after its independence from Dutch bank ABN Amro) and TVM Capital, and Easton Capital Investment Group.
Third Rock led last year’s $35m B round that also saw biotech company Genzyme’s corporate…
